751 related articles for article (PubMed ID: 12421225)
21. Correlates of hepatitis C virus (HCV) RNA negativity among HCV-seropositive blood donors.
Busch MP; Glynn SA; Stramer SL; Orland J; Murphy EL; Wright DJ; Kleinman S;
Transfusion; 2006 Mar; 46(3):469-75. PubMed ID: 16533292
[TBL] [Abstract][Full Text] [Related]
22. Probability of receiving testing in a national lookback program: the English HCV experience.
Transfusion; 2002 Sep; 42(9):1140-5. PubMed ID: 12430670
[TBL] [Abstract][Full Text] [Related]
23. Characterisation of hepatitis C virus genotype among blood donors at the regional blood transfusion centre of Ouagadougou, Burkina Faso.
Zeba MT; Sanou M; Bisseye C; Kiba A; Nagalo BM; Djigma FW; Compaoré TR; Nebié YK; Kienou K; Sagna T; Pietra V; Moret R; Simporé J
Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s54-7. PubMed ID: 24599906
[TBL] [Abstract][Full Text] [Related]
24. Routine HCV PCR screening of blood donations to identify early HCV infection in blood donors lacking antibodies to HCV.
Hitzler WE; Runkel S
Transfusion; 2001 Mar; 41(3):333-7. PubMed ID: 11274586
[TBL] [Abstract][Full Text] [Related]
25. Prospective study of the meaning of indeterminate results of the recombinant immunoblot assay for hepatitis C virus in blood donors.
Piro L; Solinas S; Luciani M; Casale A; Bighiani T; Santonocito D; Girelli G
Blood Transfus; 2008 Apr; 6(2):107-11. PubMed ID: 18946955
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis C virus (HCV) RNA among anti-HCV-positive blood donors and their recipients.
Skaug K; Li H; Jonassen TO; Larsen J; Figenschau KJ
Vox Sang; 1993; 64(4):215-9. PubMed ID: 7685969
[TBL] [Abstract][Full Text] [Related]
27. Hepatitis C virus infection in Spanish volunteer blood donors: HCV RNA analysis and liver disease.
Muñoz-Gómez R; García-Monzón C; García-Buey L; Lo Iacono O; Borque MJ; Garía-Sánchez A; Pajares JM; Moreno-Otero R
Eur J Gastroenterol Hepatol; 1996 Mar; 8(3):273-7. PubMed ID: 8724030
[TBL] [Abstract][Full Text] [Related]
28. Outcome of post-transfusion hepatitis C: disease severity in blood-component recipients and their implicated donors.
Smith BC; Chapman CE; Burt AD; Toms GL; Bassendine MF
QJM; 1997 Sep; 90(9):587-92. PubMed ID: 9349451
[TBL] [Abstract][Full Text] [Related]
29. HCV viral load in anti-HCV-reactive donors and infectivity for their recipients.
Operskalski EA; Mosley JW; Tobler LH; Fiebig EW; Nowicki MJ; Mimms LT; Gallarda J; Phelps BH; Busch MP; ;
Transfusion; 2003 Oct; 43(10):1433-41. PubMed ID: 14507276
[TBL] [Abstract][Full Text] [Related]
30. Safety of blood supply in the Caribbean countries: role of screening blood donors for markers of hepatitis B and C viruses.
Cruz JR; Pérez-Rosales MD; Zicker F; Schmunis GA
J Clin Virol; 2005 Dec; 34 Suppl 2():S75-80. PubMed ID: 16461244
[TBL] [Abstract][Full Text] [Related]
31. Insights into the epidemiology, natural history and pathogenesis of hepatitis C virus infection from studies of infected donors and blood product recipients.
Busch MP
Transfus Clin Biol; 2001 Jun; 8(3):200-6. PubMed ID: 11499958
[TBL] [Abstract][Full Text] [Related]
32. Hepatitis C viraemia in United Kingdom blood donors. A multicentre study.
Garson JA; Clewley JP; Simmonds P; Zhang LQ; Mori J; Ring C; Follett EA; Dow BC; Martin S; Gunson H
Vox Sang; 1992; 62(4):218-23. PubMed ID: 1322612
[TBL] [Abstract][Full Text] [Related]
33. Confirmation of hepatitis C infection: a comparison of five immunoblot assays.
Zaaijer HL; Vrielink H; van Exel-Oehlers PJ; Cuypers HT; Lelie PN
Transfusion; 1994 Jul; 34(7):603-7. PubMed ID: 7519796
[TBL] [Abstract][Full Text] [Related]
34. Recent Canadian experience with targeted hepatitis C virus lookback.
Goldman M; Patterson L; Long A
Transfusion; 2006 May; 46(5):690-4. PubMed ID: 16686835
[TBL] [Abstract][Full Text] [Related]
35. Transfusion-acquired hepatitis C: the Danish lookback experience. The Danish HCV [hepatitis C virus] Lookback Group.
Christensen PB; Groenbaek K; Krarup HB
Transfusion; 1999 Feb; 39(2):188-93. PubMed ID: 10037130
[TBL] [Abstract][Full Text] [Related]
36. Sensitivity and specificity of three third-generation anti-hepatitis C virus ELISAs.
Vrielink H; Zaaijer HL; Reesink HW; van der Poel CL; Cuypers HT; Lelie PN
Vox Sang; 1995; 69(1):14-7. PubMed ID: 7483486
[TBL] [Abstract][Full Text] [Related]
37. Antibody to hepatitis-C-virus-related proteins in sera from alanine-aminotransferase-screened blood donors and prospectively studied recipients.
Widell A; Sundström G; Hansson BG; Moestrup T; Nordenfelt E
Vox Sang; 1991; 60(1):28-33. PubMed ID: 1647082
[TBL] [Abstract][Full Text] [Related]
38. High rate of infectivity and liver disease in blood donors with antibodies to hepatitis C virus.
Esteban JI; López-Talavera JC; Genescà J; Madoz P; Viladomiu L; Muñiz E; Martin-Vega C; Rosell M; Allende H; Vidal X
Ann Intern Med; 1991 Sep; 115(6):443-9. PubMed ID: 1651674
[TBL] [Abstract][Full Text] [Related]
39. Prevalence & significance of hepatitis C virus (HCV) seropositivity in blood donors.
Thakral B; Marwaha N; Chawla YK; Saluja K; Sharma A; Sharma RR; Minz RW; Agnihotri SK
Indian J Med Res; 2006 Oct; 124(4):431-8. PubMed ID: 17159264
[TBL] [Abstract][Full Text] [Related]
40. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening.
Vogt M; Lang T; Frösner G; Klingler C; Sendl AF; Zeller A; Wiebecke B; Langer B; Meisner H; Hess J
N Engl J Med; 1999 Sep; 341(12):866-70. PubMed ID: 10498458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
